Overview
- Editors:
-
-
Paul-Peter Tak
-
Division of Clinical Immunology and Rheumatology EULAR & FOCIS Center of Excellence Academic Medical Center, University of Amsterdam, AZ Amsterdam, The Netherlands
- Focuses on therapeutic targets that have recently been registered or are currently under development.
- Each chapter discusses the biological rationale in great detail including results from clinical trials.
- Written by an international authorship of experts in this field.
Access this book
Other ways to access
Table of contents (12 chapters)
-
-
- Edward M. Vital, Shouvik Dass, Paul Emery
Pages 1-26
-
- Eric M. Ruderman, Richard M. Pope
Pages 27-43
-
- Yoshiyuki Ohsugi, Tadamitsu Kishimoto
Pages 45-57
-
- Wim B. van den Berg, Leo A. B. Joosten, Fons A. J. van de Loo
Pages 59-74
-
- Jagtar Nijar Singh, Iain B. McInnes
Pages 75-88
-
- Pierre Miossec, Ling Toh, Saloua Zrioual
Pages 89-101
-
-
- Zoltán Szekanecz, Alisa E. Koch
Pages 129-153
-
- Jean-Marc Waldburger, Gary S. Firestein
Pages 155-180
-
- Theresa C. Barnes, Robert J. Moots
Pages 181-191
-
- Lars C. Huber, Astrid Jüngel, Steffen Gay
Pages 193-206
-
-
Back Matter
Pages 221-228
About this book
During the past decades important breakthroughs have been made in the treatment of rheumatoid arthritis (RA). First, the implementation of low-dose methotrexate and other conventional disease-modifying anti-rheumatic drugs was introduced as an effective treatment. Second, it was recognized that early immunomodu- tory treatment is crucial for controlling the disease and its long-term destructive effects more effectively. Parallel advances in research on the pathogenesis of RA and cytokine biology converged in identifying tumor necrosis factor (TNF) as a key factor in inflammation and matrix destruction. The concept arose that elevated TNF concentrations at the sites of inflammation were driving disease pathology, and the removal of excess TNF from sites of inflammation became a therapeutic goal. Clearly, TNF blockade has revolutionized the treatment of RA, as well as other immune-mediated inflammatory diseases. Anti-TNF treatment results in cli- cal benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients who exhibited an initial response may lose response due to the development of anti-drug antibodies (human anti-chimeric antibodies and human anti-human antibodies, respectively) and perhaps as a result of escape mechanisms related to the disease process. In fact, the majority of the patients still have disease activity in at least one or two actively inflamed joints.
Editors and Affiliations
-
Division of Clinical Immunology and Rheumatology EULAR & FOCIS Center of Excellence Academic Medical Center, University of Amsterdam, AZ Amsterdam, The Netherlands
Paul-Peter Tak
